DelveInsight’s “Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-United States” Report provides an overview of the disease and market size of the CMV for United States. It also includes historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013-2023.
As per DelveInsight’s estimation, the total number of Diagnosed CMV Infection cases in United States is expected to increase at a CAGR of 0.041% to 77,726 cases in 2023. The US market size of Cytomegalovirus (CMV) infection shall reach to USD 609.88 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR of 3.71% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.55% from the year 2013-2023.As per DelveInsight’s estimation, the US Prophylaxis market is relatively higher than the therapeutic market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed historical and forecasted epidemiological data covering United States from 2013-2023.
- It also provides Market size of Cytomegalovirus (CMV) infection for United States from 2013 and forecasted Market size to 2023.
'
Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Treatment Algorithm for Cytomegalovirus Infections
Treatment for Congenital CMV Infection
Treatment of Ganciclovir resistant CMV
Treatment Guidelines
Recommendations for Treating Cytomegalovirus Infections
Disease Management
Epidemiology and Patient Population
United States
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infant Patients at High Risk of CMV
HIV Patients at High Risk of CMV in United States
Unmet Medical Needs
Marketed Products
Valcyte (Valganciclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
FOSCAVIR (foscarnet sodium)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoTect CP
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Valtrex (Valacyclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Emerging Products Analysis
Emerging Therapies
1. Approved Products
Cytovir CMV: Cell Medica Ltd.
Product Description
Research and Development
Product Development Activities
2. Pipeline Products (Phase III)
CytoTect CP 70: Biotest AG.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Letermovir: Merck & Co.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Brincidofovir: Chimerix Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
ASP0113: Astellas Pharma Global Development, Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Human Cytomegalovirus Immune Globulin: CSL Behring
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
United States Market Size
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases for United States (2013-2023)
Table 2: CMV Patients among Transplants in United States (2013-2023)
Table 3: Infants Patients at High Risk of CMV in United States (2013-2023)
Table 4: HIV Patients at High Risk of CMV in United States (2013-2023)
Table 5: United States Total Market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
